These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 5260164)

  • 1. Management of thalassemia: a comparative program.
    Wolff JA; Luke KH
    Ann N Y Acad Sci; 1969 Nov; 165(1):423-6. PubMed ID: 5260164
    [No Abstract]   [Full Text] [Related]  

  • 2. Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance.
    Graziano JH; Piomelli S; Hilgartner M; Giardina P; Karpatkin M; Andrew M; LoIacono N; Seaman C
    J Pediatr; 1981 Nov; 99(5):695-9. PubMed ID: 7299540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status of treatments with desferrioxamine B in post-transfusion hypersiderosis in children].
    Orsini A; Raybaud C; Bernard PJ; Aquaron R; Passeron P
    Mars Med; 1967; 104(4):331-7. PubMed ID: 5621537
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effects of desferrioxamine on iron elimination in children after multiple transfusions].
    Leggio ML
    Minerva Pediatr; 1966 Feb; 18(3):101-3. PubMed ID: 5930397
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term administration of desferrioxamine in thalassaemia major.
    Seshadri R; Colebatch JH; Gordon P; Ekert H
    Arch Dis Child; 1974 Aug; 49(8):621-6. PubMed ID: 4278421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.
    Constantoulakis M; Economidou J; Karagiorga M; Katsantoni A; Gyftaki E
    Ann N Y Acad Sci; 1974; 232(0):193-200. PubMed ID: 4528481
    [No Abstract]   [Full Text] [Related]  

  • 7. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen.
    Piomelli S; Danoff SJ; Becker MH; Lipera MJ; Travis SF
    Ann N Y Acad Sci; 1969 Nov; 165(1):427-36. PubMed ID: 5260165
    [No Abstract]   [Full Text] [Related]  

  • 9. Current concepts in the overall management of thalassemia.
    Propper RD
    Ann N Y Acad Sci; 1980; 344():375-83. PubMed ID: 6930877
    [No Abstract]   [Full Text] [Related]  

  • 10. Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective.
    Weiner M; Karpatkin M; Hart D; Seaman C; Vora SK; Henry WL; Piomelli S
    J Pediatr; 1978 Apr; 92(4):653-8. PubMed ID: 633033
    [No Abstract]   [Full Text] [Related]  

  • 11. Chelation therapy, transfusion requirement, and iron balance in young thalassemic patients.
    Piomelli S; Graziano J; Karpatkin M; Dudell GG; Hart D; Hilgartner M; Khanna K; Valdes-Cruz LM; Vora S
    Ann N Y Acad Sci; 1980; 344():409-17. PubMed ID: 6930881
    [No Abstract]   [Full Text] [Related]  

  • 12. Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives.
    Cantore N; Tortarolo M; Volpe E; Gonnella F; Valente A; Buonanno G
    Haematologica; 1981 Apr; 66(2):196-207. PubMed ID: 6791996
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Trans Assoc Am Physicians; 1977; 90():335-41. PubMed ID: 611665
    [No Abstract]   [Full Text] [Related]  

  • 14. Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major.
    O'Brien RT
    Ann N Y Acad Sci; 1974; 232(0):221-5. PubMed ID: 4528431
    [No Abstract]   [Full Text] [Related]  

  • 15. Chelation therapy and ferritin levels in patients with homozygous beta-thalassemia.
    Kattamis C; Lagos P; Langona E
    Prog Clin Biol Res; 1979; 34():351-9. PubMed ID: 531060
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical studies on iron chelation in patients with thalassemia major.
    Freedman MH; Olivieri N; Benson L; Liu P; McClelland R; St Louis P; Templeton D; Koren G
    Haematologica; 1990; 75 Suppl 5():74-83. PubMed ID: 2086384
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 19. [Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
    Esposito L; Ferrara M; Galdo Capotorti M
    Pediatria (Napoli); 1978 Mar; 86(1):69-76. PubMed ID: 683795
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.